Drug Pipeline News

>

Latest News

Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis
Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis

June 27th 2025

Roflumilast cream 0.05% is being studied for mild-to-moderate AD in infants aged 3 months to under 2 years in a new phase 2 trial.

FDA approves at-home belimumab autoinjector for children with lupus nephritis |© Contemporary Pediatrics
FDA approves at-home belimumab autoinjector for children with lupus nephritis

June 24th 2025

Weekly review: New PrEP for HIV, new HAE treatment, and more | Image credit: © Artur - stock.adobe.com.
Weekly review: New PrEP for HIV, new HAE treatment, and more

June 23rd 2025

FDA extends review of ruxolitinib cream for pediatric atopic dermatitis | Image credit: Contemporary Pediatrics.
FDA extends review of ruxolitinib cream for pediatric atopic dermatitis

June 20th 2025

FDA approves lenacapavir as PrEP for HIV in adults, adolescents weighing at least 35 kg | Image Credit: Contemporary Pediatrics
FDA approves twice-yearly lenacapavir as PrEP for HIV in adolescents, adults

June 18th 2025

Video Interviews

More News

© 2025 MJH Life Sciences

All rights reserved.